Milestone

Approval of Ohtuvayre™ (ensifentrine) in Macau SAR, China

US FDA approved Ohtuvayre (ensifentrine) for the maintenance treatment of COPD

Completed dosing of First Patient in Ensifentrine China Phase III Trial for COPD

Launched Bentrio™ nasal spray in Hong Kong as Asia expansion strategy

Licensed in allergy / virus prevention nasal spray Bentrio™ from Altamira

IND approval for Ensifentrine China phase 1 / 3 clinical trials for COPD

Licensed in First-in-Class COPD dual MOA PDE 3&4 inhibitor Ensifentrine from Verona Pharma

Licensed in neonatal RDS drug / device combo Aerofact™ from Aerogen Pharma

Acquired Sino Health (Yinglian) with access to 4 commercial products in emergency care and a GSP license

Licensed in post-operative pain product Ketorolac (NTM-001) from Neumentum

Raised US$ 181 million Series D equity funding

Acquired NIFEREX Iron Polysaccharide Complex Capsules

Established exclusive partnership with Aerogen Pharma on nebulizer device

Accumulatively raised US$ 80 million equity funding

Established Commercial Platform for footprint in China

Mr. Mark Lotter founded Nuance Pharma in Shanghai